Systemic sclerosis & Raynaud's
Triosephosphate isomerase (TPI1) and TPM4 are strong candidate RNA biomarkers for systemic sclerosis
Authors' conclusion
We conclude that TPI1 and TPM4 are reliable and specific biomarkers for SSc, and can be measured in blood samples with minimal risk to patients, thereby facilitating a cost-effective and timely diagnosis.
Study context
- Population
- Patients with Systemic Sclerosis (SSc) and other rheumatic diseases, and healthy controls; peripheral blood samples
- Comparison
- SSc vs healthy controls vs other rheumatic diseases
- Outcome
- Differential expression of selected candidate RNA biomarkers in peripheral blood
Methodological detailsreal-time PCR, pathway analysis (Enrichr)
- Real-time PCR
- Pathway analysis (Enrichr)
Performance
As reported in the abstract
Expression of candidate biomarkers in blood
- Overexpression of TPI1 and TPM4 in SSc vs healthy controls or other rheumatic diseases
Further findings
Pathway analysis (Enrichr)
- TPI1 and TPM4 implicated in pathways that might be involved in disease pathogenesis
Original publication
TPI1 and TPM4 are strong candidate RNA biomarkers for systemic sclerosis. Arthritis Res Ther. Published 4 February 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →